Repronex ANDA Approval On Close Identity To Pergonal Reasonable - Court
FDA's approval of an ANDA based on close chemical identities is reasonable, the Washington, D.C. court of appeals ruled Oct. 27 in vacating a lower court injunction against Ferring Pharmaceuticals' Repronex sought by Serono, manufacturer of the innovator menotropins product Pergonal.
You may also be interested in...
Aventis is trying the Premarin defense in an attempt to hold off generic competition to its antithrombotic agent Lovenox
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011